Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF) will host an investor webcast on June 3, 2026 at 8:30 a.m. ET to review updated Phase 2 CRDF-004 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer.
The updated data will first be presented in an ASCO 2026 rapid oral session on June 2, 2026.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
CRDF was up 4.55% with elevated volume while momentum peers like SKYE and ONCY screened as moving up, but scanner data flags this as a stock-specific move rather than a coordinated sector rotation.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | ASCO 2026 presentation | Positive | -7.3% | Announced rapid oral ASCO 2026 session for updated Phase 2 CRDF‑004 data. |
| Jan 27 | Positive Phase 2 update | Positive | -32.0% | Reported strong CRDF‑004 efficacy with 30 mg dose vs standard of care. |
| Dec 08 | CMML clinical data | Positive | +3.0% | Presented early onvansertib monotherapy data in CMML at ASH 2025. |
| Jul 29 | CRDF‑004 data update | Positive | -24.8% | Announced positive randomized Phase 2 CRDF‑004 data in first‑line mCRC. |
| Apr 15 | CRDF‑004 enrollment complete | Positive | -4.4% | Completed enrollment in Phase 2 CRDF‑004 trial across 41 U.S. sites. |
Clinical trial updates have generally been followed by negative price reactions, even when the data were positive.
Over the past year, Cardiff’s key news flow has centered on onvansertib’s Phase 2 CRDF‑004 program in first‑line RAS‑mutated mCRC. Events progressed from enrollment completion on Apr 15, 2025 through multiple positive data updates on Jul 29, 2025 and Jan 27, 2026, and an ASCO 2026 rapid oral presentation set for Jun 2, 2026. Despite favorable efficacy and safety signals, shares often moved lower after these clinical announcements, highlighting a pattern of weak post-news trading.
Historical Comparison
Clinical-trial-tagged headlines for CRDF have averaged a -13.09% move over five events, with multiple selloffs after strong data. This ASCO-focused CRDF‑004 update fits the ongoing pattern of meaningful trial milestones drawing cautious trading responses.
Same-tag events trace CRDF‑004’s path from enrollment completion, through successive positive randomized Phase 2 readouts, to a rapid oral ASCO 2026 presentation, underscoring continued maturation of the first-line RAS-mutated mCRC program.
Market Pulse Summary
This announcement schedules the detailed unveiling of updated Phase 2 CRDF‑004 data for onvansertib in first-line RAS‑mutated mCRC at an ASCO 2026 rapid oral session on June 2, 2026, followed by an investor webcast on June 3, 2026. In recent clinical-trial-tagged events, CRDF has often sold off after ostensibly positive onvansertib data. Investors monitoring this update may focus on how the new results compare with earlier efficacy and safety signals and how they inform potential registrational plans.
Key Terms
phase 2 medical
plk1 inhibition medical
folfiri medical
folfox medical
bevacizumab medical
metastatic colorectal cancer medical
mcrc medical
AI-generated analysis. Not financial advice.
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it will host an investor webcast featuring members of management on June 3, 2026 at 8:30 am ET to review updated data from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care regimens (FOLFIRI/bevacizumab or FOLFOX/bevacizumab) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC).
The updated CRDF-004 data will first be presented during a rapid oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2026 at 8:00 am CT/9:00 am ET and will build on the CRDF-004 data previously presented in January 2026. More details about the oral presentation are available on the Company’s website here and the full abstract is now available on the ASCO website.
Investor Webcast Details
The investor webcast will take place on June 3 at 8:30 am ET. To register for and access the live webcast, please visit the “Events” page of the Cardiff Oncology website.
About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated metastatic colorectal cancer (mCRC). In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 2 trial in second-line RAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational trial in first-line patients with RAS-mutated mCRC.
Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
For more information, please visit https://www.cardiffoncology.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
